Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bate

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
ACS Medicinal Chemistry Letters|March 19, 2020
Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion InjuryJonathan E Palmer, Breanna M Brietske, Tyler C Bate, et al.
British Journal of Cancer|December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaJ M G Larkin, S A Hughes, D A Beirne, et al.
Journal of Virology|July 15, 2003
Evaluation of quinacrine treatment for prion diseasesA Barret, F Tagliavini, G Forloni, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
ACS Medicinal Chemistry Letters|March 19, 2020
Reactive Oxygen Species (ROS)-Activatable Prodrug for Selective Activation of ATF6 after Ischemia/Reperfusion InjuryJonathan E Palmer, Breanna M Brietske, Tyler C Bate, et al.
British Journal of Cancer|December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaJ M G Larkin, S A Hughes, D A Beirne, et al.
Journal of Virology|July 15, 2003
Evaluation of quinacrine treatment for prion diseasesA Barret, F Tagliavini, G Forloni, et al.
Pageof 3